|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0144576,
umls-concept:C0201734,
umls-concept:C0205179,
umls-concept:C0205195,
umls-concept:C0280100,
umls-concept:C0332174,
umls-concept:C1275555,
umls-concept:C1442162,
umls-concept:C1522690,
umls-concept:C1550718
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2004-9-15
|
|
pubmed:abstractText |
We aimed to define the maximum tolerated dose (MTD) and characterize the toxicity of the combination of pegylated liposomal doxorubicin (PLD; Caelyx trade mark ) and weekly paclitaxel (wPTX), and to investigate pharmacokinetics of PLD in this combination.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1566-73
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:15367419-Adult,
pubmed-meshheading:15367419-Aged,
pubmed-meshheading:15367419-Aged, 80 and over,
pubmed-meshheading:15367419-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15367419-Doxorubicin,
pubmed-meshheading:15367419-Drug Administration Schedule,
pubmed-meshheading:15367419-Female,
pubmed-meshheading:15367419-Humans,
pubmed-meshheading:15367419-Liposomes,
pubmed-meshheading:15367419-Male,
pubmed-meshheading:15367419-Maximum Tolerated Dose,
pubmed-meshheading:15367419-Middle Aged,
pubmed-meshheading:15367419-Neoplasms,
pubmed-meshheading:15367419-Neutropenia,
pubmed-meshheading:15367419-Paclitaxel
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors.
|
|
pubmed:affiliation |
Department of Medical Oncology, University of Ioannina, Ioannina, Greece. briasou@otenet.gr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|
